Viewing Study NCT04622566


Ignite Creation Date: 2025-12-24 @ 4:38 PM
Ignite Modification Date: 2026-01-28 @ 4:01 AM
Study NCT ID: NCT04622566
Status: UNKNOWN
Last Update Posted: 2020-11-13
First Post: 2020-10-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Sponsor: Peking University Cancer Hospital & Institute
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mucosal Melanoma View
None Neoadjuvant Treatment View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pembrolizumab View
None Lenvatinib View